A reduction in long-term spatial memory persists after discontinuation of peripubertal GnRH agonist treatment in sheep by Hough, D. et al.
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a  b  s  t  r  a  c  t
Chronic  gonadotropin-releasing  hormone  agonist  (GnRHa)  administration  is  used  where  suppression  of
hypothalamic-pituitary-gonadal  axis  activity  is  beneﬁcial,  such  as  steroid-dependent  cancers,  early  onset
gender dysphoria,  central  precocious  puberty  and  as a reversible  contraceptive  in  veterinary  medicine.
GnRH  receptors,  however,  are  expressed  outside  the  reproductive  axis,  e.g.  brain  areas  such  as  the  hip-
pocampus  which  is  crucial  for  learning  and memory  processes.  Previous  work,  using  an  ovine  model,
has  demonstrated  that  long-term  spatial  memory  is  reduced  in  adult  rams  (45 weeks  of  age),  follow-
ing peripubertal  blockade  of  GnRH  signaling  (GnRHa:  goserelin  acetate),  and  this  was  independent  of  the
associated  loss  of  gonadal  steroid  signaling.  The  current  study  investigated  whether  this  effect  is reversed
after  discontinuation  of  GnRHa-treatment.  The  results  demonstrate  that peripubertal  GnRHa-treatment
suppressed  reproductive  function  in  rams,  which  was  restored  after  cessation  of  GnRHa-treatment  at  44
weeks of  age,  as indicated  by similar  testes  size  (relative  to body  weight)  in  both  GnRHa-Recovery  and
Control  rams  at 81  weeks  of  age.  Rams  in which  GnRHa-treatment  was  discontinued  (GnRHa-Recovery)
had  comparable  spatial  maze  traverse  times  to  Controls,  during  spatial  orientation  and  learning  assess-
ments  at  85  and 99  weeks  of age. Former  GnRHa-treatment  altered  how  quickly  the  rams  progressed
beyond  a speciﬁc  point  in  the  spatial  maze  at 83  and  99 weeks  of age,  and  the  direction  of this  effect
depended  on  gonadal  steroid  exposure,  i.e.  GnRHa-Recovery  rams  progressed  quicker during  breeding
season  and  slower  during  non-breeding  season,  compared  to Controls.  The  long-term  spatial  memory
performance  of  GnRHa-Recovery  rams  remained  reduced  (P <  0.05,  1.5-fold  slower)  after  discontinuation
of  GnRHa,  compared  to Controls.  This result  suggests  that  the  time  at  which  puberty  normally  occurs
may  represent  a critical  period  of  hippocampal  plasticity.  Perturbing  normal  hippocampal  formation  in
this  peripubertal  period  may  also  have  long  lasting  effects  on  other  brain  areas  and  aspects  of  cognitive
function.
© 2016  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license. IntroductionGonadotropin-releasing hormone (GnRH) is a hypothalamic
ecapeptide that, following its release from axon terminals at the
edian eminence, stimulates the release of luteinizing hormone
∗ Corresponding author.
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(LH) and follicle stimulating hormone (FSH) from the pituitary
gland. GnRH can also reach the central nervous system (CNS),
as GnRH neurones in the hypothalamus can have axons that
extend into other regions of the CNS including the limbic system
(Silverman et al., 1987). In addition, GnRH can cross the blood-
brain barrier, from the median eminence, into the third ventricle
cerebrospinal ﬂuid, albeit with low efﬁciency (Caraty and Skinner,
2008). GnRH receptor expression has been demonstrated at sites
within the CNS (Jennes et al., 1997; Albertson et al., 2009; Schang
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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( D. Hough et al. / Psychoneu
t al., 2011) and a range of peripheral tissues (Hapgood et al., 2005;
kinner et al., 2009). Thus, when GnRH analogs are used therapeu-
ically in human and veterinary medicine, it is also important to
onsider the effects at these non-reproductive sites.
As GnRH agonists (GnRHa) result in continued receptor stimu-
ation, as opposed to ultradian cyclic changes, theiradministration
nitially results in an increase in LH and FSH secretion (‘ﬂare-effect’),
ollowed by the down-regulation of GnRH receptor expression in
he pituitary gland and suppression of reproductive axis function
Garner, 1994; Chen and Eugster, 2015). GnRHa is typically pre-
cribed when the suppression of the reproductive axis is required,
uch as steroid-sensitive conditions like prostate cancer, uterine
broids and endometriosis (Garner, 1994). In children and adoles-
ents, GnRHa can be prescribed for treatment of central precocious
uberty (CPP) (Chen and Eugster, 2015) and gender dysphoria (GD)
Hembree et al., 2009) to temporarily halt reproductive develop-
ent.
Carel et al. (2009) emphasized the need for investigation of
he potential psychological effects associated with peripuber-
al GnRHa-treatment in CPP. Similarly, the potential effects of
nRHa-treatment on cognition during this important develop-
ental period are not well characterized. Wojniusz et al. (2016)
ecently demonstrated that peripubertal GnRHa increases emo-
ional reactivity (i.e. emotional and behavioral responses to a fearful
ituation) in girls with CPP, whereas resting heart rate decreased
nd this effect was more pronounced with longer durations of
nRHa-treatment. Studies, using an ovine model, have also demon-
trated that peripubertal GnRHa-treated rams display increased
isk-taking behavior (Wojniusz et al., 2011), altered emotional reac-
ivity (Evans et al., 2012) and reduced long-term spatial reference
emory (Hough et al., 2016). Physiological changes within the
imbic system have also been reported in this ovine model, as
eripubertal GnRHa-treatment alters amygdala volume (Nuruddin
t al., 2013a) and the expression of hippocampal genes that are
nvolved in endocrine signaling and synaptic plasticity (Nuruddin
t al., 2013b). With this growing body of evidence that peripuber-
al GnRHa-treatment may  affect development of cognitive function,
here is now a requirement to investigate whether these effects are
eversible when GnRHa-treatment is discontinued.
In the current study, we investigated whether effects from
eripubertal GnRHa-treatment, persisted in rams following the dis-
ontinuation of treatment. Speciﬁcally, we investigated whether
he previously reported reduction in long-term spatial memory
ersists, or if effects on spatial orientation and learning emerge
ater in life, following the discontinuation of peripubertal GnRHa-
reatment.
. Materials and methods
.1. Animals
All animal procedures were conducted at the University of Glas-
ow Cochno Farm and Research Centre (55◦ 55′N) under Home
fﬁce Regulations (Project License: 60/4422). The experimental
nimals used in this study were Scottish Mule, Texel cross males,
orn from same sex litters between 23 March and 12 April 2013. At
irth, lambs were assigned to one of the treatment groups described
elow. Lambs from twin and triplet pregnancies were allocated to
ifferent groups, so that only 1 sibling was represented in each
reatment group. Puberty was delayed in the GnRHa-Recovery
GnRHa-Rec, n = 25) lambs by subcutaneous implantation of the
nRHa, goserelin acetate (Zoladex 3.6 mg,  kindly donated by Astra
eneca, Macclesﬁeld, UK), every four weeks from 8 to 44 weeks of
ge (average age of pubertal onset in male sheep is 10 weeks of age
Wood and Foster, 1998) and are expected to be sexually competentocrinology 77 (2017) 1–8
within the ﬁrst year of life). Control (n = 30) and GnRHa-Rec rams
were grazed on pasture, except during behavioral trials, when they
were housed indoors with ad libitum access to hay or silage, with
supplements as deemed necessary by standard management prac-
tices. All animals were euthanized at the end of the study period,
when they were approximately 2 years of age.
2.2. Testes development
Approximately every four weeks, morphometric data were
collected from all animals, including testes size, to monitor the
effectiveness of GnRHa to suppress the reproductive axis. Scrotal
length and circumference were measured with a tailor tape mea-
sure while sheep were held in a sitting-position. Testes size was
calculated from the scrotal length × circumference and normal-
ized to body weight. Testes size data at 28 (ﬁrst breeding season),
44 (ﬁrst anestrus), 81 (second breeding season) and 99 (second
anestrus) weeks of age are presented, as these measurements were
nearest to the dates of spatial maze performance assessment.
2.3. Assessment of spatial orientation and learning
This study used modiﬁcations of the assessment techniques and
spatial mazes described previously (Hough et al., 2016), as it follows
on from this study on the effects of chronic peripubertal GnRHa-
treatment (with/without testosterone supplementation) on spatial
orientation, learning and memory in rams from 8 to 45 weeks of
age. The current study reports analyses of spatial maze perfor-
mance data following the discontinuation of GnRHa-treatment at
44 weeks of age. Speciﬁcally, performance was  evaluated at 83 and
95 weeks of age, and compared to that observed at 41 weeks of age
(Hough et al., 2016) when the GnRH-Recovery group was  still being
treated with GnRHa.
2.3.1. Spatial orientation and learning
Sheep were individually assessed in spatial maze Layout 1 of
Fig. 1 at 41 weeks of age, and in Layout 2 of Fig. 1 at 83 and 95
weeks of age. A change in maze layout was necessary, as some
of the sheep were already familiar with the former layout (used
in long-term spatial memory assessment at 45 weeks of age as
reported by Hough et al., 2016). Each sheep was given three maze
attempts within the same day (each attempt separated by ∼2 h) to
traverse the maze and reunite with ﬂock members in the audience
pen. Approximately 30 sheep were assessed per day and kept in the
audience pen throughout the day with ad libitum access to water
and hay. During each maze attempt, a sheep was calmly ushered
from the audience pen to the start of the maze. Sheep that failed to
complete the maze within a 5 min  time limit, were ushered back to
the audience pen via the maze entrance so that the correct route
remained unknown. On the last attempt of the day, unsuccessful
sheep proceeded to the audience pen via the quickest route Spatial
orientation was  assessed as the performance of sheep in the ﬁrst
spatial maze attempt of the day, at each age. Spatial learning was
assessed as the performance of sheep over three maze attempts
within the same day, at each age.
2.3.2. Recorded observations
Spatial performance was individually assessed by recording tra-
verse times (min: s: ms), i.e. the time taken to move from the
entrance to the ﬁnish line (5 min  = incomplete), as well as recod-
ing the progress through the maze as the time difference to move
between lines A to E, judged on the placement of a front leg across
the line. Emotional reactivity was not assessed in this study, as only
a few vocalizations, escape attempts, urinations and defecations
were observed at 83 and 95 weeks of age.
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Fig. 1. Spatial maze layouts that were used in this study, with letters indicating zones that contain the same traps across all layouts, but presented in a different order or
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ong-term spatial memory at 99 weeks of age. Layout 3 was used for the novel maz
.4. Assessment of long-term spatial memory
Long-term spatial memory was assessed as described previously
Hough et al., 2016).
.4.1. Training
Education and conﬁrmation runs were performed, over two
ays, at 95 weeks of age, in the maze layout used in the assess-
ent of spatial orientation and learning (Layout 2, Fig. 5). The
ducation runs were completed when a sheep was  able to tra-
erse the maze within 1 min  on two successive attempts. The
etention of this ability was tested in the conﬁrmation run, which
onsisted of two attempts to complete the maze within 1 min.
f unsuccessful, sheep repeated the cycle of education and con-
rmation runs, with a maximum of 3 cycles within the same
ay. The total number of attempts during the education and con-
rmation runs was recorded for each ram, together with the
uickest traverse time, to serve as a measure of the ease of train-
ng.
.4.2. Long-term spatial memory
Retention of long-term spatial memory was assessed 4 weeks
fter training was completed (99 weeks of age), in the same maze
esign. Each sheep was given one maze attempt, and traverse
imes (incomplete = 5 min) and progress through maze zones was
ecorded. The proportion of time spent in each zone was  calculated
or each animal as a percentage of total time spent in the maze.
.4.3. Familiarity in a novel maze design
Immediately after assessment of long-term memory, each sheep
as given one attempt to traverse a new spatial maze layout (Lay-
ut 3, Fig. 1), which contained the same ‘traps’ but in a different
rder or orientation. Maze traverse times (incomplete = 5 min) and
rogress through maze zones were recorded..5. Statistical analysis
Data were excluded from analysis where performance was
udged to have been compromised because of temporary weeks of age, respectively. Layout 2 was used for training and the assessment of
ssment at 99 weeks of age.
incapacity, i.e. health concerns. In addition, data were excluded
from analysis where animals escaped from the maze area or jumped
over internal maze walls. Exclusion of data was done by specifying
a missing value for the relevant response variable(s) in that partic-
ular maze attempt (number of observations is speciﬁed in Fig. 3).
All statistical analyses were performed with R software (Version
3.2.1, © 2015 The R Foundation for Statistical Computing Plat-
form) using the RStudio interface (Version 0.99.467, © 2009–2015
RStudio Inc.). Response variables were analyzed using the gener-
alized linear model (glm) function; ram identity was included as
an explanatory variable, to account for individual variation across
time or respective maze attempts.
The effect of GnRHa on body weight and normalized testes size,
were analyzed using a: (1) Two-way ANOVA (Treatment × Age)
in year 1 and 2, (2) Two-way ANOVA during breeding and
non-breeding season. Effects of age and treatment on spatial ori-
entation were assessed with data from the ﬁrst attempt of the
maze, across all ages (41, 83 and 95 weeks of age), using a two-way
ANOVA (Treatment × Age). Effects of treatment on spatial learning,
over three consecutive maze attempts, were assessed with two-
way ANOVA (Treatment × Maze attempt) at each respective age.
One-way ANOVA was  used to assess the effects of treatment on the
ease of maze training (number of training attempts at 95 weeks of
age), as well as traverse times upon completion of training. Effects
of treatment on long-term spatial memory were tested by com-
parison of traverse times at: (1) 99 weeks of age only (one-way
ANOVA); (2) 95 (last training attempt) versus 99 (the assessment
attempt) weeks of age (two-way ANOVA: Treatment × Time); and
99 (GnRHa-Recovery) versus 45 (during GnRHa-treatment) weeks
of age (two-way ANOVA: Treatment × Time). The effect of maze
design familiarity was examined by comparison of the traverse time
of maze layouts 1 and 2 at 83 weeks of age, or layouts 2 and 3 at
95 weeks of age (two-way ANOVA: Treatment × Maze Layout). The
effects of treatment and age on testes size was evaluated with a
two-way ANOVA. All statistical tests were followed by a Tukey Hon-
est Signiﬁcant Difference post hoc test, to assess where signiﬁcant
differences existed between treatment groups. All graphs represent
means and standard errors of the mean. Statistical P-values ≤ 0.05
were considered signiﬁcant.
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Fig. 2. Testicular size mean ± s.e.m., as a factor of body weight, during GnRHa-treatment in the ﬁrst year, and after discontinuation of GnRHa-treatment in the second year,
of  life relative to Control rams. Measurements were taken during the breeding seasons at 28 and 81 weeks of age. Non-breeding season measurements occurred at 44 and
99  weeks of age. Different letters on top of bars indicate signiﬁcant differences in the means across both years. Control: no treatment; GnRHa: peripubertal GnRHa-treated
from  8 to 44 weeks of age; GnRHa-Rec: GnRHa-treatment discontinued at 44 weeks of age.
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. Results
.1. Body weight and testes development
There was no difference (P > 0.05) in body weight between the
ontrol and GnRHa-treated rams at any age. Peripubertal GnRHa-
reatment signiﬁcantly (P < 0.01) suppressed normalized testes
ize, compared to Control rams, at both 28 and 41 weeks of age
Fig. 2). In the GnRH-Rec group, normalized testes size increased
igniﬁcantly (P < 0.001) by 25% over the 37 weeks following dis-
ontinuation of GnRHa-treatment. Normalized testes size during
he breeding season in the second year of life, being 47% higher
ompared to the breeding season of the previous year. At 81 and
9 weeks of age, there was no difference (P > 0.05) in normalized
estes size between Control and GnRHa-Rec groups.
.2. Spatial orientation – completion of maze at the ﬁrst attempt
.2.1. Traverse times
The average time taken for sheep to traverse the maze (Fig. 3)
as signiﬁcantly (P < 0.001) different over the three ages tested.
ompared to 41 weeks of age (Layout 1), average traverse times
t 83 and 95 weeks of age were 84 and 62% slower, respectively.
 different maze layout was used at 83 weeks of age (Layout 2) to
hat used at 41 weeks of age, and comparison of these two  ages
nly, indicated a tendency (P = 0.082) for average traverse times to
e longer at 83 weeks of age; an effect that was  seen equally in
oth groups (Controls: 2.92 ± 0.29 vs. 3.47 ± 0.30 min; GnRHa-Rec:
.96 ± 0.38 vs. 3.49 ± 0.26 min).
There were no signiﬁcant effects (P > 0.05) of treatment or the
nteraction between the effects of treatment and age, on mean tra-
erse times. orientation and learning assessments, over three maze attempts within the same
 particular age. Control: no treatment; GnRHa: peripubertal GnRHa-treated from 8
3.2.2. Progress through the maze
There were no signiﬁcant effects of treatment, or interaction
between the effects of age and treatment, on the proportion of time
spent in any of the maze zones (Fig. 4, Attempt 1). Regardless of
age (P > 0.05), rams spent the greatest proportion of time in zones
C and E. However, rams spent signiﬁcantly (P < 0.001) more time in
zones A and B, and signiﬁcantly (P < 0.01) less time in zone D, at 95
compared to 83 weeks of age.
3.3. Spatial learning – completion of maze with same-day
repeated attempts
3.3.1. Traverse times
The mean times taken to complete the maze across all three
attempts within the same day, at each age, are shown in Fig. 3
and the P-value summary is reported in Table 1. There was  no
signiﬁcant (P > 0.05) difference in spatial learning between the Con-
trol and GnRHa-Rec groups, at any age and no signiﬁcant (P > 0.05)
interaction between treatment and age. Signiﬁcant improvement
in traverse times over the three attempts were seen at 41 (P < 0.01),
83 (P < 0.001) and 95 (P = 0.050) weeks of age, but at 83 weeks of
age the improvement (P < 0.001) was greater in the new maze lay-
out with a 29.7% decrease in traverse times from the ﬁrst to second
attempt, and 10.7% from the second to third attempt.
3.3.2. Progress through the maze
The mean proportion of time spent in each maze zone, for the
two groups of animals, are shown in Fig. 4 with the associated P-
value summary in Table 1. At 41 weeks of age, there was no effect
of treatment on the time spent in any maze zone. At 83 weeks of
age, on the ﬁrst attempt, animals spent most time in zones B, C
and E. On the second attempt, the proportion of time spent in each
D. Hough et al. / Psychoneuroendocrinology 77 (2017) 1–8 5
Fig. 4. Mean ± s.e.m. proportionate time spent in each zone of the maze, expressed here as a percentage of the total time spent in the maze during spatial orientation and
learning  assessment at 83 and 95 weeks of age over three maze attempts. Control: no treatment; GnRHa-Rec: GnRHa-treatment discontinued at 44 weeks of age. *P < 0.05.
Table 1
Spatial learning. Summary of two-way ANOVA P-values to assess the effects of treatment on spatial performance across all three maze attempts within the same day at ages
41,  83 and 95 weeks. P-values in bold are statistically signiﬁcant (P < 0.05) those in italics are where there is a trend (P < 0.1).
Response Variable 41wks 83wks 95wks
Treatment Attempt Treatment × Attempt Treatment Attempt Treatment × Attempt Treatment Attempt Treatment × Attempt
Traverse time 0.226 0.001 0.566 0.552 <0.001 0.790 0.394 0.050 0.440
Proportion of time
Zone A 0.508 0.076 0.827 0.368 <0.001 0.734 0.450 0.018 0.417
Zone  B 0.853 0.010 0.915 0.021 0.860 0.647 0.403 0.486 0.895
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eZone  C 0.273 <0.001 0.373 0.610 
Zone  D 0.597 <0.001 0.783 0.441 
Zone  E 0.180 0.380 0.743 0.905 
one was more equal, with the exception of zone E, where animals
pent the greatest proportion of time. By the third attempt, the
ime spent in each zone was approximately equal. These changes
n the pattern of maze progression were reﬂected by a signiﬁcant
P < 0.01) increase in the proportion of time spent in zones A (1st
rap) and D (4th trap), and a signiﬁcant (P < 0.001) decrease in the
roportion of time spent in zone C (3rd trap) over the course of the
hree attempts. The GnRHa-Rec group spent signiﬁcantly (P < 0.05)
ess time in zone B than the Control group, particularly in attempt
. The GnRHa-Rec group also tended (P = 0.080) to spend less time
n zone E in attempt 1, but more time in this zone in attempt 3,
ompared to Controls.
At 95 weeks of age, progress through the maze during the ﬁrst
ttempt followed a similar pattern to that seen at 83 weeks of age,
ith the most time being spent in zones C and E. On the second
ttempt, there was a reduction in the proportionate time spent
n these zones, together with a statistically signiﬁcant increase
P < 0.05) in the proportion of time spent in zones A and D, but this
attern change was not as marked as seen at 83 weeks of age. The
roportion of time spent in zone C tended (P = 0.057) to decrease
ith each maze attempt in the Controls, so that they spent nearly
qual proportions of time across all zones by attempt 3, but the
nRHa-Rec group still spent most of their time in zones C and E,
ven in attempt 3.<0.001 0.126 0.128 0.065 0.057
0.006 0.286 0.726 0.005 0.812
0.145 0.080 0.207 0.280 0.879
3.4. Long-term spatial memory
3.4.1. Traverse times
Fig. 5+A depicts the mean traverse times at the end of train-
ing (‘Trained < 1min’), and 4 weeks later when performance was
assessed in the same maze (‘Long-term memory’) and in a novel
maze design (‘Novel maze’). There were no effects of treatment on
the number of attempts required to complete the training (Con-
trols 6.6 ± 0.8; GnRHa-Rec 7.1 ± 0.9 attempts) or traverse times
at the end of training. Compared to traverse times at the end
of training, all animals took signiﬁcantly (P < 0.001) longer to
traverse the maze during long-term memory assessment, and
GnRHa-treatment signiﬁcantly exaggerated this effect (Treatment
P = 0.041, Treatment × Time P = 0.041), as GnRH-Rec and Control
animals were 2-fold and 1.3-fold slower, respectively.
When animals were tested in a novel spatial maze, the tra-
verse times were similar (P = 0.564) for GnRH-Rec and Control
animals. Comparison of individuals’ performances in the long-
term spatial memory and novel maze assessments, indicated
that all animals took signiﬁcantly (Familiarity P < 0.001) longer to
complete the novel maze, irrespective of treatment group (Treat-
ment × Familiarity P = 0.146). The increase in traverse time was
signiﬁcantly affected by treatment (P = 0.008), whereby Control ani-
mals took 1.6-fold longer, and GnRH-Rec animals only took 1.1-fold
6 D. Hough et al. / Psychoneuroendocrinology 77 (2017) 1–8
Fig. 5. Spatial performance during long-term spatial memory and novel maze assessments at 99 weeks of age. (A) Mean ± s.e.m. traverse times after training was completed
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(‘Trained < 1min’), and 4 weeks later in the same familiar maze design (‘Long-term
ones  during long-term spatial memory assessment; and (C) during novel maze ass
est.  Control: no treatment; GnRHa-Rec: GnRHa-treatment discontinued at 44 wee
onger, to complete the novel maze compared to the long-term
emory assessment.
.4.2. Progress through the maze
The mean proportion of time spent in each maze zone during
he long-term spatial memory and novel maze assessments are
hown in Fig. 5B and C. During the long-term memory assessment,
he proportion of time spent in the maze zones was  not different
etween the GnRHa-Rec and Control groups, although there was
 trend (P = 0.079) for the Control group to spend a proportionally
reater time in zone B compared to the GnRHa-Rec group.
When animals were tested in the novel maze, progress through
he maze zones was not affected by treatment, but animals spent
igniﬁcantly (P < 0.05) less time in the last three zones of the novel
aze compared to the ‘familiar’ maze layout used in the long-term
patial memory assessment.
. Discussion
Following the discontinuation of GnRHa-treatment at 44 weeks
f age, the reproductive axis was no longer suppressed, as testes
ize increased to a similar size as untreated rams by 83 weeks
f age and was larger at the time of the breeding versus non-
reeding season. This provides evidence that endogenous GnRH
nd gonadal steroid signaling was restored. This delayed expo-
ure to gonadal steroid signaling did not alter the speed at which
nimals completed the spatial tasks during assessments of spatial
rientation (i.e. ﬁrst maze attempt) and learning (progress over
 same-day maze attempts) after peripubertal GnRHa-treatment
ad ceased, but affected the manner in how quickly rams moved
eyond a speciﬁc point within the maze, over three same-day
ttempts. On assessment of long-term spatial memory at 99 weeks
f age, GnRHa-Rec rams took longer to traverse a familiar spatial
ask, 4 weeks after training, than age-matched Controls, whereas
heir performance during an unfamiliar spatial task was the same
s the Controls. This reduction in long-term spatial memory in
nRHa-Rec animals was also observed prior to the withdrawal
f GnRHa-treatment (Hough et al., 2016) and the current study
herefore reports that this reduction persisted into adulthood
nd was not reversed after the discontinuation of peripubertal
nRHa-treatment. A detailed discussion on these main observa-
ions follows below.
.1. Spatial orientation and learning.1.1. Prior to GnRHa withdrawal
Although peripubertal GnRHa-treatment did not have profound
ffects on spatial orientation (i.e. ﬁrst maze attempt) and learning
i.e. change over 3 same-day maze attempts) during the ﬁrst year ofory’) or an unfamiliar maze design (‘Novel maze’). (B) Progression through maze
nt. Different letters above bars indicate signiﬁcant differences from Tukey post hoc
ge.
life (Wojniusz et al., 2011; Hough et al., 2016), peripubertal GnRHa-
treatment was associated with alterations to the manner in which
rams moved within the maze. This was evidenced by a decreased
motivation to complete the maze and increased emotional reac-
tivity within the maze, but did not have a signiﬁcant effect on the
pattern of progression through the maze zones. Supplementation
of peripubertal GnRHa-treatment with exogenous gonadal steroids
counteracted the effects of GnRHa on motivation and emotional
reactivity.
4.1.2. After GnRHa withdrawal
Given the observations in the ﬁrst year of life, it is not surprising
that after discontinuation of GnRHa-treatment in the second year
of life, traverse times during assessments of spatial orientation and
learning were unaffected in the GnRHa-Rec group. Interestingly,
maze progression over three same-day attempts in the GnRHa-Rec
group was quicker at 83, but slower at 95 weeks of age, compared
to Controls. As breeding and non-breeding seasons are represented
at 83 and 95 weeks of age, respectively, it could be indicative that,
in the GnRHa-Rec rams, high gonadal steroid levels had a greater
impact to improve the ability of rams to learn how to progress
beyond a speciﬁc point in the spatial maze, compared to the Con-
trols. The manifestation of these differences in maze progression
patterns during the second year of life, suggests that the program-
ming of motivational behavior and/or emotional reactivity might
be dependent on exposure to gonadal steroids during a critical win-
dow of development which coincides with the peripubertal period.
4.2. Long-term spatial memory
4.2.1. Prior to GnRHa withdrawal
As reported previously (Hough et al., 2016), during the ﬁrst year
of life, peripubertal GnRHa-treated rams required 1.3-fold more
training attempts to learn how to complete the spatial maze than
untreated rams. This effect was counteracted with testosterone
supplementation, indicating that the ease of training was inﬂu-
enced by testosterone, rather than GnRH signaling.
Long-term spatial memory performance was also reduced in
peripubertal GnRHa-treated rams, compared to Control rams (1.5-
fold). As supplementation of the GnRHa-treatment with exogenous
testosterone did not counteract this reduction, it indicated that
long-term spatial memory is affected by the loss of GnRH, rather
than testosterone, signaling.
Lastly, the assessment of rams in a spatial maze with a novel
layout demonstrated that testosterone counteracted the effects of
peripubertal GnRHa-treatment to reduce the spatial performance
of rams. This indicated that testosterone, rather than GnRH, sig-
naling inﬂuenced the ability of rams to solve a spatial task where
familiar cues were presented in a novel sequence.
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.2.2. After GnRHa withdrawal
The present study reports that, after GnRHa withdrawal the ease
ith which animals could be trained to complete a spatial maze
n the second year of life was not different from Controls. Thus
he deﬁcit in training ability observed during peripubertal GnRHa-
reatment was not permanent and a delayed exposure to gonadal
teroids was sufﬁcient to restore the speed of spatial maze training.
During the assessment of long-term spatial memory at 99 weeks
f age, GnRHa-Rec rams were found to be 1.5-fold slower than Con-
rols in traversing the spatial maze. Interestingly this difference
elative to the Controls is of the same magnitude as those reported
hen animals were receiving GnRHa-treatment (Hough et al.,
016). The maintenance of this difference in spatial performance,
ollowing the discontinuation of peripubertal GnRHa-treatment,
emonstrated that the effects of peripubertal GnRHa on long-term
patial memory were not reversed and persisted into adulthood,
espite the restoration of normal GnRH and gonadal steroid sig-
aling. This result indicates that long-term spatial memory is
ependent on changes that occurred during a critical window of
evelopment that is sensitive to alterations in GnRH signaling.
hese changes might be related to neural plasticity and endocrine
ignaling as suggested by Nuruddin et al. (2013b). Spatial memory
an be subdivided into long-term spatial reference memory, which
ategorizes spatial information according to cues that remain the
ame between spatial tasks (Olton and Papas, 1979) and work-
ng spatial memory, which categorizes information based on the
equence of spatial cues (Olton and Papas, 1979). As the perfor-
ance of the Control and GnRHa-Rec rams were comparable at
9 weeks of age in the novel maze, which effectively tests spatial
orking memory, it can be concluded that the observed perma-
ent effects of peripubertal GnRHa-treatment on long-term spatial
emory is speciﬁc to spatial reference memory. It is also reason-
ble to argue that the increase in circulating testosterone, which
hould have accompanied gonadal development in the GnRHa-Rec
roup, must have been sufﬁcient to eliminate any effects of the
eripubertal GnRHa-treatment on spatial working memory.
.3. Implications for discontinuing peripubertal
nRHa-treatment
To our knowledge, this is the ﬁrst report that the effects of
eripubertal GnRHa-treatment to reduce long-term spatial ref-
rence memory will persists following GnRHa withdrawal and
uggests that these effects are permanent. Studies on the use of
nRHa in adult humans (Freedland et al., 2009; Green et al., 2000)
ave reported impaired cognition and memory loss, which were
scribed to the associated loss of estrogen and/or testosterone. Beer
t al. (2006) reported that long-term memory was reduced, in terms
f compromised immediate and delayed verbal memory, in men
ith prostate cancer and androgen deprivation (primarily GnRHa-
ediated) compared to untreated healthy Controls. Another study,
n elderly men  with prostate cancer and GnRHa-mediated andro-
en deprivation (Salminen et al., 2004), reported that a decline in
estosterone was associated with slower visuo-motor speed, slower
eaction times relating to working memory, reduced recognition
peed and delayed recall of letters, but improved object recall.
hese observations support the conclusion of the current ovine
tudy that spatial working memory is reduced by the loss of testos-
erone, and that restoration of testosterone, either via replacement
herapy (Hough et al., 2016) or gonadal development following
nRHa-withdrawal, results in normal function. However, deﬁcits
n long-term spatial reference memory did not improve with expo-
ure to endogenous testosterone and are likely permanently altered
y the changes in GnRH signaling that occurred during the peripu-
ertal period. In so doing, it identiﬁes the peripubertal period as
 critical window of development with regard to spatial memory,ocrinology 77 (2017) 1–8 7
in which GnRH signaling is involved. The observation that peripu-
bertal GnRHa-treatment is associated with permanent changes in
brain development raises particular concerns about the cognitive
changes associated with the prolonged use of GnRHa-treatment in
children and adolescents.
Limited studies have looked at the long-term effects of GnRHa-
treatment on cognition in children and adolescents. One study
reported that 3-year GnRHa-treatment of girls with early pubertal
onset was associated with a 7% reduction in IQ (Mul et al., 2001).
This effect was hypothesized to be attributed to the suppression of
sex steroids and their effect on brain development which resulted in
a more age-appropriate IQ (Mul  et al., 2001). A recent study of girls
treated with GnRHa for CPP, reported that they exhibited increased
emotional reactivity and a decreased resting heart rate (Wojniusz
et al., 2016). Interestingly, the changes in heart rate observed in
that study were dependent upon the duration of GnRHa-treatment.
Taken with the results of this study – in which it is indicated that
peripubertal GnRHa-treatment affects aspects of cognitive function
– it may  be worth considering the duration of the GnRHa-treatment
in children and adolescents, and limiting it where possible (Hayes,
2016).
The results of this study when considered with those of Hough
et al., 2016 suggest that there is a critical period of brain devel-
opment associated with the peripubertal period. For early onset
GD, GnRHa is prescribed from childhood, throughout the adoles-
cent period and into early adulthood, when an informed decision
can be made about gender reassignment. This prolonged treatment
that may  encompass such critical developmental periods, however,
may  be justiﬁed by the increased risk of life-threatening behav-
iors (e.g. risk taking and suicide attempts), the effects of which
could outweigh any minor cognitive and psychological impacts
of GnRHa-treatment (Grossman and D’Augelli, 2007; Vance et al.,
2014). For CPP, GnRHa-treatment commences from the time of
diagnosis of early pubertal onset (8 or 9 years of age for girls or boys,
respectively) and continues until approximately 11 years of age
(Carel et al., 2009), with the main goal to increase predicted adult
height by allowing more time for growth prior to the fusion of bones
during puberty. However, this goal has been primarily achieved
when GnRHa-treatment commenced with pubertal onset < 6 years
of age (Carel et al., 2009; Hayes, 2016). The question then remains
whether GnRHa exposure can be limited in children with pubertal
onset between 6 to 8 or 9 years of age, or if GnRHa-treatment can
be discontinued earlier than 11 years of age.
While continuous GnRHa-treatment may limit psychological
problems in CPP, the decision to commence GnRHa-treatment
needs further exploration (Carel et al., 2009) as proper parental
and physician support might be an alternative intervention (Hayes,
2016). It has been suggested by Steinberg (2004) that a special
window of susceptibility to psychosocial and psychopathological
conditions exists during adolescence, which is created by the tem-
poral gap between the onset of puberty and late adolescence. At
the onset of puberty there are changes in the limbic system and
increasing reward sensitivity, whereas the maturation of the pre-
frontal cortex is slower and age-dependent so that self-regulatory
systems are only developed in late adolescence. In this regard,
early-maturing children would experience a greater vulnerabil-
ity towards risk-taking and novelty-seeking behavior, as well as
psychopathological conditions, than children that enter puberty at
an older age (Steinberg, 2004). This is evidenced by correlations
between early pubertal onset and a relatively young age of ﬁrst sex-
ual intercourse, increased incidence of drug and alcohol abuse, as
well as increased risk of sexual abuse (Mul  and Hughes, 2008; Kim
and Lee, 2012; Hayes, 2016). Against this background, the reduc-
tion in long-term spatial memory following peripubertal GnRHa,
as observed in the rams in this study, might not outweigh the risks
involved in withholding this treatment, but provides evidence that
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ome cognitive functions may  be irreversibly altered by peripu-
ertal GnRHa-treatment. Further investigation on other potential
ognitive and psychosocial effects are required – including whether
hese effects are reversible or sexually dimorphic – to assist in mak-
ng informed decisions about the timing of the commencement and
iscontinuation of peripubertal GnRHa-treatment.
. Conclusion
Spatial orientation and learning performance (i.e. traverse
imes) were not different from untreated rams, when assessed at
3 and 95 weeks of age, following the discontinuation of peripu-
ertal GnRHa-treatment at 44 weeks of age. However, the effects
f peripubertal GnRHa-treatment to increase emotional reactiv-
ty, persisted into the second year of life after GnRHa-treatment
ad been discontinued, because the manner in which rams moved
hrough the maze (i.e. maze progress pattern) over multiple same-
ay maze attempts differed from the Controls. Interestingly, these
spects of how the rams progressed through a maze appeared to
e dependent on the level of gonadal steroid exposure (i.e. quicker
aze progression during breeding season vs. slower maze progres-
ion during non-breeding season).
The reduction in long-term spatial memory induced by peripu-
ertal GnRHa-treatment persisted in rams into adulthood even
fter GnRHa-treatment was  discontinued. Development of this cog-
itive function is, therefore, likely to occur during a critical window
f development, which may  reﬂect a time-limited period of hip-
ocampal plasticity. Perturbations in GnRH signaling during this
eripubertal period may  also have long lasting effects on other
rain areas and/or aspects of cognitive function.
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